Convenient on-the-go solution for immunity and wellness
DSIP is not a standard insomnia medication, and it is not a replacement for diagnosing the underlying cause of poor sleep
doi: 10.3389/fendo.2025.1586589 Received 03 March 2025 Accepted 29 April 2025 Published 21 May 2025 Volume 16 - 2025 Edited by Giacomina Brunetti, University of Bari Aldo Moro, Italy Reviewed by Nagesha Guthalu Kondegowda, City of Hope, United States Nikita Nirwan, Jamia Hamdard University, India Updates Copyright 2025 Chen, Lyu, Zhao, Han, Huang, Yang and Zhou
Willow currently describes access to compounded semaglutide injections, oral dissolving semaglutide tablets, and compounded tirzepatide injections when a physician determines treatment is appropriate
Human medical use remains uncertain because BPC-157 lacks FDA approval, standardized dosing, and strong controlled clinical evidence